Investor Relations

Company Overview

Agentix Corp. is a clinical-stage biotechnology company that is dedicated to the development of therapies for metabolic diseases, including type 2 diabetes (T2D), obesity, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

There is a need for more treatments as the manifestations of metabolic disease continue to be prevalent in the USA. According to the CDC, over 30 million Americans have T2D¹ and approximately 100 million US adults are obese². Furthermore, an estimated 64 million US adults have NAFLD³. Of those with obesity, over 9% of cases are considered to be severe while it is predicted that 20% of NAFLD cases will progress to NASH.

1. https://www.cdc.gov/diabetes/data/statistics-report/index.html
2. https://www.cdc.gov/obesity/data/adult.html
3. https://liverfoundation.org/for-patients/about-the-liver/diseases-of-the-liver/nonalcoholic-steatohepatitis-information-center/nash-definition-prevalence/